|

National Longitudinal Cohort of Hematological Diseases (NICHE) - CART

RECRUITINGSponsored by Institute of Hematology & Blood Diseases Hospital, China
Actively Recruiting
SponsorInstitute of Hematology & Blood Diseases Hospital, China
Started2021-06-01
Est. completion2026-12-31
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06607289

Summary

This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical trials and real-world studies of Chimeric antigen receptors (CAR) T cell therapy will be established in China. Patient-level data from these studies will be collected to create a large real-world cohort. In addition, patients receiving CAR-T cell therapy for hematological malignancies identified from an existing hematology longitudinal cohort study, the National Longitudinal Cohort of Hematological Diseases (NICHE), will also be included in the study.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients with clinically diagnosed hematologic malignancies
* Patients treated with CAR-T cell therapy
* Signed the informed consent form

Conditions2

CancerHematological Malignancies

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.